Protective effect of L-pipecolic acid on constipation in C57BL/6 mice based on gut microbiome and serum metabolomicOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study asked whether L-pipecolic acid, a metabolite reduced in constipated children, can relieve constipation. It combined a human observational arm with a mouse treatment experiment. Stool and serum from children were profiled by 16S rDNA sequencing and UPLC-Q/TOF-MS metabolomics. Differential microbes and metabolites were correlated. A loperamide-induced constipation model in mice then tested L-pipecolic acid. Fecal parameters, intestinal transit, serum and colon serotonin, and colonic 5-HT4R and AQP3 gene expression were measured.
Who was studied?
The human arm enrolled 26 children with functional constipation and 28 healthy children in Hefei, China. Patients were aged 1 to 13 (14 boys, 12 girls) and met Rome IV criteria. None had taken antibiotics, probiotics, or prebiotics in the prior three months. Blood and fecal samples were collected. The animal arm used female C57BL/6 mice aged 6 to 8 weeks. They were split into control, loperamide, and loperamide-plus-L-pipecolic-acid groups (6 mice per group).
What were the most important findings?
Constipated children had significantly lower gut microbial alpha diversity and 45 differential metabolites. Serum L-pipecolic acid was significantly reduced (234,435 versus 175,209, p=0.0439), and genera Phascolarctobacterium and Ochrobactrum fell. In mice, L-pipecolic acid raised fecal water content (p=0.0251) and intestinal transit rate (p=0.0005), and shortened first black stool time (p=0.0004). It increased serum and colon serotonin and 5-HT4R messenger RNA, while lowering the water channel AQP3 messenger RNA (p=0.0002).
What are the greatest implications of this study?
The findings suggest L-pipecolic acid may help prevent or treat constipation. It appears to act by boosting serotonin signalling through 5-HT4R and reducing colonic water reabsorption via AQP3. This links a gut-microbiome-associated metabolite to a plausible mechanism for slowed transit. The metabolite tracks with specific altered genera. The human sample was small and observational, and efficacy was shown only in a chemically induced mouse model. Human trials would be needed before clinical use.